Menu
Not yet recruiting NCT07562724

Diet and WB-EMS Effects in Obesity

No phase Interventional Obesity & Overweight Metabolic Disorders Electrotherapy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Energy-Restricted Diet, Whole-Body Electromyostimulation (WB-EMS).
Who it may be relevant to
Registry conditions: Obesity & Overweight, Metabolic Disorders, Electrotherapy. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effects of Energy-Restricted Diet and Whole-Body Electromyostimulation (WB-EMS) on Myokine-Adipokine Interaction, Appetite Regulation, and Body Composition in Obese Individuals: A Randomized Controlled Trial

Overview

Obesity is a major global health problem associated with metabolic dysfunction, altered adipokine signaling, and impaired appetite regulation. Conventional weight loss strategies such as calorie restriction often result in compensatory physiological adaptations, including increased appetite and loss of lean body mass, which may limit long-term effectiveness. Whole-body electromyostimulation (WB-EMS) is an emerging, time-efficient intervention that induces simultaneous muscle activation and may improve metabolic health. However, the underlying molecular mechanisms, particularly the interaction between myokines and adipokines, remain insufficiently understood. This randomized controlled trial aims to investigate the effects of an energy-restricted diet combined with WB-EMS on myokine-adipokine interaction, appetite regulation, and body composition in obese individuals. Participants will be randomly assigned to either a diet-only group or a diet plus WB-EMS group for 8 weeks. Primary outcomes include changes in serum irisin levels. Secondary outcomes include myostatin, leptin, adiponectin, FGF-21, ghrelin, GLP-1, body composition parameters, and eating behavior. The findings of this study are expected to provide novel insights into the physiological and molecular effects of WB-EMS as a complementary strategy in obesity management.

Interventions

  • Behavioral Energy-Restricted Diet
    A personalized diet with approximately 750 kcal/day energy deficit.
  • Device Whole-Body Electromyostimulation (WB-EMS)
    Whole-body electromyostimulation applied 2-3 times per week for 8 weeks under supervision.

Primary outcome measures

  • Change in serum irisin levels [Time frame: Baseline to 8 weeks]
Secondary outcome measures (10)
  • Change in serum myostatin levels [Time frame: Baseline to 8 weeks]
  • Change in serum leptin levels [Time frame: Baseline to 8 weeks]
  • Change in serum adiponectin levels [Time frame: Baseline to 8 weeks]
  • Change in serum FGF-21 levels [Time frame: Baseline to 8 weeks]
  • Change in serum ghrelin levels [Time frame: Baseline to 8 weeks]
  • Change in serum GLP-1 levels [Time frame: Baseline to 8 weeks]
  • Change in fat mass [Time frame: Baseline to 8 weeks]
  • Change in fat-free mass [Time frame: Baseline to 8 weeks]
  • Change in body fat percentage [Time frame: Baseline to 8 weeks]
  • Change in eating behavior scores [Time frame: Baseline to 8 weeks]

Eligibility criteria

Inclusion criteria

  • Age between 18 and 65 years
  • Body mass index (BMI) ≥ 30 kg/m²
  • Sedentary lifestyle (less than 2 hours of structured exercise per week)
  • Willingness to participate and provide written informed consent

Exclusion criteria

  • Presence of pacemaker or implantable cardioverter-defibrillator
  • Known cardiovascular disease or severe chronic illness
  • Pregnancy or breastfeeding
  • Uncontrolled diabetes or severe metabolic disorders
  • Active malignancy or cancer treatment
  • Severe renal or hepatic failure
  • Acute infection or inflammatory disease
  • Orthopedic conditions limiting physical activity
  • Use of medications affecting body composition or appetite (e.g., corticosteroids, weight-loss drugs)
  • Regular resistance training within the last 3 months
  • Substance abuse, including alcohol or drug dependency
  • Psychiatric or cognitive conditions affecting adherence to the study protocol

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Turkey (Türkiye) · 2 centers
  • Dicle University — Diyarbakır
  • Firat University — Elâzığ

Identifiers

NCT: NCT07562724 · FU_MGBeydagi_EMS_B_2026/05

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗